SAT0336 Change over Time in the Profile of Ankylosing Spondylitis Patients Treated with Infliximab in A REAL World Routine Care

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 713.3-714
Author(s):  
D. Choquette ◽  
M. Starr ◽  
M. Khraishi ◽  
W. Bensen ◽  
S. Shaikh ◽  
...  
2020 ◽  
Vol 12 ◽  
pp. 1759720X2094908
Author(s):  
Maria G. Tektonidou ◽  
Gkikas Katsifis ◽  
Athanasios Georgountzos ◽  
Athina Theodoridou ◽  
Eftychia-Maria Koukli ◽  
...  

Objective: Our aim was to evaluate the effect of adalimumab on work productivity measures, overall activity impairment, and sleep quality in patients with active moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated in routine care settings in Greece and determine factors associated with work impairment and sleep disturbance. Methods: Patients with active moderate to severe RA ( n = 184), PsA ( n = 166), and AS ( n = 150) were enrolled in this 24-month, prospective, observational study at 80 hospital outpatient clinics and private practices throughout Greece. Patients received adalimumab alone or in combination with standard antirheumatic therapies according to routine care. Work productivity and sleep were assessed through two patient-reported outcome measures: the Work Productivity and Activity Impairment–General Health questionnaire and the Medical Outcomes Study Sleep Scale (MOS-SS). Pearson correlation coefficients were estimated to assess the association of work impairment and sleep disturbances with disease activity scores. Results: In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3–24.5%); n = 100]; presenteeism [40.0% (33.8–46.3%); n = 98], overall work productivity impairment [46.8% (40.4–53.2%); n = 94], activity impairment [47.0% (44.3–49.6); n = 421], and the MOS-SS sleep problems index [31.6 (29.5–34.1); n = 421] after 24-month treatment ( p < 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( p < 0.05). Improvements in overall work impairment and sleep disturbance positively correlated with improvements in disease activity measures. Conclusion: Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.


2020 ◽  
Author(s):  
Proton Rahman ◽  
Michael Starr ◽  
Derek Haaland ◽  
Louis Bessette ◽  
Michelle Teo ◽  
...  

Abstract Background: The objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety. Methods: AS patients who were eligible for treatment with IFX or subcutaneous GLM as per their respective Canadian product monographs were enrolled into the BioTRAC registry from 2005-2017. The study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed by changes in clinical outcomes and acute phase reactants. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates. Results: A total of 389 IFX- and 421 GLM-treated patients were enrolled. A significant decrease in disease duration at baseline was observed in the IFX cohort, from a median of 8.0 in 2005-2008 to 1.0 years in 2009-2015 (p<0.001). A reduction in baseline BASFI score (p=0.011) and proportion of patients in ASDAS very high disease activity (p=0.004) was also observed over time. Meanwhile, in the GLM cohort, most disease parameters remained similar from 2010-2017.Treatment with both agents significantly improved all disease parameters over time with similar efficacy between the two agents. The incidence of AEs and SAEs were 136 and 131 events/100 PYs and 10.5 and 8.45 events/100 PYs for IFX- and GLM-treated patients, respectively. Conclusion: Both IFX and GLM treatment in AS significantly reduced disease activity in most outcome measures in a similar fashion and were well tolerated in Canadian routine care. Trial Registration: NCT00741793


2018 ◽  
pp. 213-234
Author(s):  
Simon Glynn

The success of linguistic communication in general, and translation in particular, is dependent upon the veracity of our understanding of the meaning of concepts signified in or by a language or languages. This raises the question as to how such understanding may be accomplished and ensured. And while Platonists and their ilk rely upon the transcendental intuition of supposedly absolute concepts, purportedly inscribed in their souls, those skeptical of such metaphysics have tended to attempt to derive the meaning of the concepts signified by language ostensively from observations of the supposedly “Real” world. However, in this essay, I argue that this is problematic for a number of reasons, not the least being that, as Husserl, following Hume, has noted, even the existence, much less the nature, of a (quasi-Noumenal) “Real” world, outside or transcending our experiences of phenomenal “Appearances,” is no more empirically verifiable than is Plato’s transcendental realm. Nor may understanding of (the meaning of ) the concepts signified by the linguistic communications of others be derived from these appearances, since my understanding of how things appear to others presupposes my understanding of the language they must employ to communicate this to me. Furthermore, and contra Husserl, as Hermeneutic Phenomenologists such as Heidegger recognized, the very appearances from which we may seek to drive our concepts are always already mediated by our conceptions or preconceptions. All of this being so, then as we shall perhaps not be surprised to see, the (semantic meaning of ) concepts signified by language are, as de Saussure has argued, derived from the syntactic relations which delineate them. Consequently, as Derrida has shown, they change over time (or diachronically) as such relations change. Unable therefore to establish the veracity of individuals’ understanding of concepts communicated either within a single language, or between languages, by appealing outside language to an independent criterion of arbitration, we must instead rely upon the coherence of linguistic articulation and communication; a coherence which, although a necessary condition of ensuring the correspondence of our understanding with that of others, can never be sufficient to do so. However, confidence in our understanding increases with the specificity and number of communications achieved without the occurrence of incoherence.


2020 ◽  
Author(s):  
Proton Rahman ◽  
Michael Starr ◽  
Derek Haaland ◽  
Louis Bessette ◽  
Michelle Teo ◽  
...  

Abstract Background: The objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety. Methods: AS patients who were eligible for treatment with IFX or subcutaneous GLM as per their respective Canadian product monographs were enrolled into the BioTRAC registry from 2005-2017. The study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed by changes in clinical outcomes and acute phase reactants. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates. Results: A total of 389 IFX- and 421 GLM-treated patients were enrolled. A significant decrease in disease duration at baseline was observed in the IFX cohort, from a median of 8.0 in 2005-2008 to 1.0 years in 2009-2015 (p<0.001). A reduction in baseline BASFI score (p=0.011) and proportion of patients in ASDAS very high disease activity (p=0.004) was also observed over time. Meanwhile, in the GLM cohort, most disease parameters remained similar from 2010-2017.Treatment with both agents significantly improved all disease parameters over time with similar efficacy between the two agents. The incidence of AEs and SAEs were 136 and 131 events/100 PYs and 10.5 and 8.45 events/100 PYs for IFX- and GLM-treated patients, respectively. Conclusion: Both IFX and GLM treatment in AS significantly reduced disease activity in most outcome measures in a similar fashion and were well tolerated in Canadian routine care. Trial Registration: NCT00741793


2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Proton Rahman ◽  
Michael Starr ◽  
Derek Haaland ◽  
Louis Bessette ◽  
Michelle Teo ◽  
...  

Abstract Background The objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety. Methods AS patients who were eligible for treatment with IFX or subcutaneous GLM as per their respective Canadian product monographs were enrolled into the BioTRAC registry from 2005 to 2017. The study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed by changes in clinical outcomes and acute phase reactants. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates. Results A total of 389 IFX- and 421 GLM-treated patients were enrolled. A significant decrease in disease duration at baseline was observed in the IFX cohort, from a median of 8.0 in 2005–2008 to 1.0 years in 2009–2015 (p < 0.001). A reduction in baseline BASFI score (p = 0.011) and proportion of patients in ASDAS very high disease activity (p = 0.004) was also observed over time. Meanwhile, in the GLM cohort, most disease parameters remained similar from 2010 to 2017. Treatment with both agents significantly improved all disease parameters over time with similar efficacy between the two agents. The incidence of AEs and SAEs were 136 and 131 events/100 PYs and 10.5 and 8.45 events/100 PYs for IFX- and GLM-treated patients, respectively. Conclusion Both IFX and GLM treatment in AS significantly reduced disease activity in most outcome measures in a similar fashion and were well tolerated in Canadian routine care. Trial registration NCT00741793.


Author(s):  
Jeremy Freese

This article examines four basic issues regarding ‘preferences’ as an explanatory concept in analytical sociology. First, it explains how the ontology of preference should be understood; that is, the question of what preferences are. It challenges both the ideas that preferences are ‘mental events’ and that they are ‘behavioral tendencies.’ Second, given that real-world alternatives may be characterized by numerous different attributes, the article considers the question of which attributes may be most salient to understanding action. It also explores the link between personality and preferences and how organizations act according to preferences. Finally, it describes how preferences change over time, paying attention to the preferences of actors being a target of purposive action by others and by actors themselves.


Author(s):  
Simone Villa ◽  
Fabio Stella

Non-stationary continuous time Bayesian networks are introduced. They allow the parents set of each node in a continuous time Bayesian network to change over time. Structural learning of nonstationary continuous time Bayesian networks is developed under different knowledge settings. A macroeconomic dataset is used to assess the effectiveness of learning non-stationary continuous time Bayesian networks from real-world data.


Sign in / Sign up

Export Citation Format

Share Document